Growth factor-1 deficiency treatment

On 24 May 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 373. The active ingredient is mecasermin for treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects.